Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Once the trial is over you will no longer be provided with the trial treatment. You and your doctor will be informed of the results which will also be published in a medical journal, so that others can benefit from the research. If the trial proves that fenofibrate does reduce diabetic retinopathy, it is likely that this information will be included in major guidelines which doctors use to treat diabetes. That will allow many people with diabetes to be offered fenofibrate.

After the trial ends, we would also like your permission to continue to monitor your health confidentially from a range of medical records using existing electronic systems in the same way that we will be doing during the trial. This is to allow the LENS researchers to study the effect of 3-5 years of fenofibrate treatment for many years to come. Permission will be required from NHS Scotland’s Public Benefits and Privacy Panel for Health and Social Care before any such work is undertaken to ensure that it is done to the highest standards and in accordance with the Data Protection Act.